Amylin Analogs Market Size & Share, by Application (Type 1 Diabetes, Type 2 Diabetes); Drug Type; Distribution Channel; Route of Administration; End user- Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

Amylin Analogs Market - Regional Analysis

North America Market Insights

North America in the amylin analogs market is projected to account for the highest share of 40% during the forecast timeline. The market’s growth in the region is propelled by the presence and availability of strong medical spending as well as a rise in obesity rates. For instance, as stated in the NIDDK report in September 2021, approximately 42.4% of the adult population in the U.S. readily suffers from obesity. Besides, the U.S. effectively dominates the region with the overall regional demand, attributed to expansion in insurance coverage and the adoption of private insurers. Also, Canada caters the regional revenue due to administrative controls and provincial formulary additions.

The market in the U.S. is readily dominating the region mainly due to the obesity epidemic. Besides, the obesity cost in the U.S. healthcare system is nearly USD 173 billion per year, according to CDC report in January 2025. On the other hand, Medicare spending in 2021 is USD 829 billion and is expected to increase by 18% in the upcoming years, based on the KFF data in January 2023. Moreover, a private insurer provides coverage of cagrilintide scripts that result in AHRQ-driven cost savings. Also, hospital-centric distribution along with combination therapies are other trends that are proactively amplifying the market in the country.

The amylin analogs market in Canada is continuously growing, which is attributed to the existence of provincial healthcare investments. For instance, the CMA report in 2025 states that nearly 30% to 40% of provincial and territorial budgets are taken by the healthcare sector, which positively impacts the market growth in the country. Meanwhile, there are other factors, including the presence of cold chain gaps, along with price regulations, that positively contribute to market upliftment.

Prevalence of Obesity in Adults in 2023

Source: CDC September 2024

APAC Market Insights

The amylin analogs market in the Asia Pacific is the fastest-growing region in the world and is fueled by a high and escalating burden of type 2 diabetes and obesity, especially in highly populated countries. Main drivers for the market are escalating healthcare spending, enhanced diagnosis rates, and increased knowledge of innovative therapeutic solutions beyond conventional insulin. Of particular note is the growth of government-sponsored programs and health care reforms that have seen wider coverage of chronic disease management, resulting in an enhanced access by patients to these expensive treatments.

Japan's market is defined by extensive government spending and a fast aging population with a high incidence of type 2 diabetes. The NLM report in April 2022 states that the annual healthcare expenditure in Japan is 59.5 trillion JPY facilitating broad access under the national health insurance. A central trend is the accelerated approval and reimbursement of innovative biologics, which is necessitated by the necessity to control the disease burden of the elderly population effectively and reduce long-term healthcare expenditure.

China leads the market in the APAC region and is driven by its enormous patient base and increasing government investment in chronic disease management. Statistics from the National Medical Products Administration indicates that the medical support funds in 2023 were 74.5 billion yuan. The primary trend is the integration of newer, more effective analogs into the National Reimbursement Drug List (NRDL), which dramatically expands patient access and drives market volume, even as price negotiations pressure unit costs.

Europe Market Insights

Europe in the amylin analogs market is expected to account for a considerable share by the end of the forecast duration. According to the July 2024 eurostat report, an estimated 63.6% of the adult population age from 65 to 74 in the region is readily affected by obesity. In addition, the region also constitutes streamlined administrative acceptances through the EMA PRIME scheme that positively influences the market upliftment. Besides, Germany has been deliberately leading with growth rate since 2021. Meanwhile, the UK caters the largest regional healthcare budget, thus denoting a positive outlook for market growth.

The market in Germany is projected to capture the highest of the overall regional revenue by the end of 2035. This is effectively driven by the presence of an efficient reimbursement system and a surge in the occurrence of obesity. Besides these factors, the country has made an expenditure of €501 billion, which also includes amylin therapies in 2024, of which 12% yearly growth, as per Statistisches Bundesamt (Destatis) in 2025. Moreover, regional hospitals currently stock cagrilintide, owing to the availability of G-BA mandates for metabolic care services, thus suitable for market growth in the country.

The amylin analogs market in the UK is projected to hold a considerable regional revenue during the forecast period. This upliftment is mainly driven by the budget allocation by the NHS. The UK's growth is fueled by a well-defined patient pathway within the National Health Service (NHS) and strategic government initiatives targeting obesity and diabetes prevention. According to the Association of the British Pharmaceutical Industry (ABPI), navigating the NICE technology appraisal process is critical for market access. Meanwhile, the market is shaping due to the NHS's centralized procurement program, with R&D incentives that are meant to increase local production.